Government
As the 2020 election heats up, candidates for president are unveiling their plans to lower prescription drug prices.
In November 2018, Chinese researcher He Jiankui announced he had used CRISPR gene editing to modify the CCR5 genes in the embryos of seven Chinese couples. This was met by widespread condemnation, investigations and a call for a global moratorium against that type of research.
MIT’s Research Enterprise in Singapore, SMART, launches a new research group, Critical Analytics for Manufacturing Personalized-Medicine (CAMP), as part of Singapore’s National Cell Manufacturing Initiative to overcome scientific and technical challenges in life-changing cell therapies.
Although the American public, Congress and the Trump administration have pressed for meaningful legislation over drug pricing, time is running out this year.
The National Institute of Health Research has announced £135m of funding for new research projects across the UK to tackle some of the biggest health conditions, including dementia.
Turning away from “low-value” (waste, overuse) towards “high-value” health care is critical for the sustainability of solidarity-based healthcare systems. The Ludwig Boltzmann Institute for Health Technology Assessment is represented on the European Expert Panel.
The World Health Organization developed a five-year plan to promote regulatory collaboration and reliance around the world and to assist national regulatory authorities in solving related issues.
Some members of the Trump administration worried that passing the rebates directly to consumers would cost the federal government too much in the long run.
Reckitt Benckiser spun Indivior off into a standalone company in 2014. Earlier this year the Department of Justice charged Indivior for its role in the opioid crisis.
The FDA approval marks the first drug approved for Azurity, a company formed from the merger of CutistPharma and Silvergate.
PRESS RELEASES